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The human DOC-2/DAB2 interactive protein (hDAB2IP) gene is a novel member of the Ras GTPase-activating family and has been
demonstrated to be a tumour-suppressor gene inactivated by methylation in several cancers. In this study, we analysed the
methylation and expression status of hDAB2IP in gastrointestinal tumours. The promoter region of hDAB2IP was divided into two
regions (m2a and m2b) based on our previous report, and the methylation status was determined by bisulphite DNA sequencing in
gastric cancer cell lines. The gene expression was semiquantified by real-time RT–PCR, and the results indicated that the m2b
promoter region might be an authentic methylation-mediated key regulator of the gene expression. Based on the sequence data, we
developed a methylation-specific PCR (MSP) for the m2a and m2b regions and applied it to the samples. Methylation-specific PCR
revealed aberrant methylation in the m2a region in eight of 12 gastric cancer cell lines (67%), 16 of 35 gastric cancer tissues (46%) and
29 of 60 colorectal cancer tissues (48%), and in the m2b region in eight of 12 cell lines (67%), 15 of 35 gastric cancer tissues (43%)
and 28 of 60 colorectal cancer tissues (47%). On the other hand, seven (12%) and 11 (19%) of 59 gastrointestinal nonmalignant
mucosal specimens showed methylation in the m2a and m2b regions, respectively, suggesting that hDAB2IP methylation might play a
causative role in carcinogenesis. The 5-aza-20-deoxycytidine treatment restored the gene expression in the m2b-methylated cell lines,
confirming that the methylation caused gene downregulation. We also examined the relationship between hDAB2IP methylation and
the clinicopathological features in patients with primary tumours, and determined that methylation in the m2b region was associated
with location of the tumour in the stomach. In summary, our results demonstrated that hDAB2IP methylation is frequently present in
gastrointestinal tumours and that the resulting gene silencing plays an important role in gastrointestinal carcinogenesis.
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Aberrant methylation of normally unmethylated CpG islands
located in the 50 promoter region of genes has been shown to be
associated with transcriptional inactivation of several genes in
human cancers, including gastrointestinal tumours, and appears to
serve as an alternative to mutational inactivation (Jones and Laird,
1999; Baylin and Herman, 2000).
The human DOC-2/DAB2 interactive protein gene (hDAB2IP),
located on chromosome 9q33.1–q33.3, is a novel member of the
Ras GTPase-activating family (Tseng et al, 1998; Chen et al, 2002;
Wang et al, 2002). It interacts directly with the DOC-2/DAB2 (also
known as differentially expressed in ovarian carcinoma-2, DOC-2)
protein that appears to be a tumour suppressor in malignant
tumours, including mammary, prostate and ovarian cancers
(Fulop et al, 1998; Zhou and Hsieh, 2001). hDAB2IP and DAB2
form a unique protein complex and exert a negative regulatory
activity on the Ras-mediated signal pathway (Wang et al, 2002).
Recently, it was reported that the P2 region ( 598 to þ44) of the
hDAB2IP gene shows promoter activity, and that transcriptional
silencing by aberrant methylation of the P2 region is critical
tumorigenesis in prostate cancer (Chen et al, 2003) and breast
cancer (Dote et al, 2004).
In this study, we examined the methylation and expression
status of hDAB2IP in a series of gastric cancer cell lines, and
developed the methylation-specific PCR (MSP) assay for hDAB2IP
for application to gastrointestinal tumour samples. To clarify the
mechanism of gene silencing, the cell lines were treated with 5-aza-
20-deoxycytidine (5-Aza-CdR) and/or trichostatin A (TSA) to
examine the effect of methylation and histone deacetylation on the
gene silencing. In addition, we analysed the relationship between
the methylation status and the clinicopathological features in cases
with surgically resected gastric and colorectal cancers, in order to
investigate the clinical and pathogenetic importance of hDAB2IP
methylation in gastrointestinal tumours.
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Cell lines
In all, 12 cell lines derived from human gastric cancer were used in
this study. Four gastric cancer cell lines of MKN series (MKN-1,
adenosquamous cell carcinoma; MKN-28 and MKN-74, well-
differentiated adenocarcinoma; MKN-45, poorly differentiated
adenocarcinoma) and KATO-III (signet ring cell carcinoma) were
kindly provided from Professor K Shimizu (Department of
Molecular Genetics, Okayama University Graduate School of
Medicine and Dentistry, Okayama, Japan). NCI-SNU-5 and NCI-
SNU-16 (poorly differentiated adenocarcinoma) were obtained
from the American Type Culture Collection (Manassaa, VA, USA).
The other five cell lines (MKN-7, well-differentiated adenocarci-
noma; NUGC-4, signet ring cell carcinoma; SH-10-TC, poorly
differentiated adenocarcinoma; AZ521 and H-111-TC, well-differ-
entiated adenocarcinomas) were obtained from Cell Resource
Center for Biomedical Research, Tohoku University. Most cells
were grown in RPMI1640 (Sigma Chemical Co., St Louis, MO,
USA) supplemented with 10% heat-inactivated fetal bovine serum
and incubated in 5% CO2.
Clinical samples
Surgically resected specimens of 35 primary gastric cancers, 60
primary colorectal cancers and 59 matched corresponding
nonmalignant mucosa specimens were obtained from Okayama
University Hospital, Okayama, Japan after acquiring informed
consent from each patient between 1998 and 2002. Patient
demographics were shown in Table 1. Histological classification
and tumour staging were carried out according to Lauren
classification (Lauren, 1991) and the TNM Stage Grouping (Sobin
and Fleming, 1997). Peripheral blood lymphocytes were obtained
from five healthy volunteers. The whole procedure was approved
by the Appropriate Institutional Review Board of our centre.
DNA extraction and bisulphite treatment
DNA from cell lines and specimens was subjected to bisulphite
treatment as described previously (Dote et al, 2004). Briefly for
bisulphite treatment, 1mg of genomic DNA was denatured by
NaOH and modified by sodium bisulphite, which converts all
unmethylated cytosines to uracils while methylated cytosines
remain unchanged (Wang et al, 1980). The modified DNA was
purified using a Wizard DNA cleanup system (Promega, Madison,
WI, USA).
Map of 50-flanking region of hDAB2IP and bisulphited
DNA sequencing analysis
Our previous report identified the promoter region of hDAB2IP
(P2) that was divided into m2a (237bp) and m2b (401bp) regions
(Chen et al, 2003). The location of the CpG dinucleotides, P2, m2a
and m2b regions in the 50-flanking region of hDAB2IP (GenBank
accession number AL365274) are shown in Figure 1A. The m2a
and m2b were amplified and PCR amplicons were cloned into
pCR2.1-TOPO Vector and sequenced following our previous report
(Chen et al, 2003). To determine the methylation status of
hDAB2IP, individual eight clones from each sample were
sequenced by the Applied Biosystems PRISM dye terminator cycle
sequencing method (Perkin-Elmer Corp., Foster City, CA, USA)
using forward and reverse M13 primers.
hDAB2IP mRNA expression by semiquantitative real-time
RT–PCR
Total cellular RNA was isolated from cell lines and five
nonmalignant gastric mucosa specimens with RNeasy minikit
(Qiagen Sciences, MD, USA) according to the manufacturer’s
instructions and then treated with 2unitsml
 1 of DNase I (Ambion,
Austin, TX, USA) for 30min at 371C. RT reaction was performed
for 2mg of total RNA with the SuperScript II First-strand Synthesis
using the Oligo (dT) primer system (Invitrogen Life Technologies,
Inc., Carlsbad, CA, USA) in 20ml reaction mixture. cDNAs were
semiquantified by fluorescence-based real-time RT–PCR using
TaqMan technology (Perkin Elmer Corp., Foster City, CA, USA)
with the Gene Amp 5700 Sequence Detection System (Perkin Elmer
Corp.). TATA box binding protein (TBP) was used to normalise
the expression of hDAB2IP (Pawlowski et al, 2000; Toyooka et al,
2001). The sequences of the primers and probe for hDAB2IP and
TBP expression were previously reported. We used serial dilutions
of the positive control cDNA to create a standard curve. The
expression ratio was defined as the hDAB2IP PCR products
compared to those of the TBP, multiplied by 100. All experiments
were performed in duplicate.
MSP assay
The methylation-specific primers were designed based on the
bisulphited DNA sequencing data of gastric, breast (Dote et al,
2004) and lung (data not shown) cancer cell lines, whose
expressions were remarkably downregulated (see below). The
location of MSP primers was shown in Figure 1A and B. The
methylation status of m2a and m2b regions in gastric and
colorectal cancers was determined by MSP (Herman et al, 1996).
The methylated and unmethylated alleles for m2a and m2b regions
were amplified using hDAB2IPm2a-MSP-F and hDAB2IPm2a-
MSP-R for methylated m2a, hDAB2IPm2b-MSP-F and hDA-
B2IPm2b-MSP-R for methylated m2b, hDAB2IPm2a-USP-F and
hDAB2IPm2a-USP-R for unmethylated m2a, and hDAB2IPm2b-
USP-F and hDAB2IPm2b-USP-R for unmethylated m2b. The PCR
products were resolved by electrophoresis in a 2% agarose gels
containing ethidium bromide. The normal lymphocyte DNA that
was treated with Sss1 methyltransferase (New England BioLabs,
Table 1 Clinical characteristics of studied gastric and colorectal cancer
patients
Variables
No. of informative
gastric cancer cases
(%)
No. of colorectal
cancer informative
cases (%)
Sex
Male 21 (60) 37 (62)
Female 14 (40) 23 (38)
Tumour invasion
T 1 6 (17) 4 (7)
T 2 14 (40) 4 (7)
T 3 11 (31) 45 (75)
T 4 4 (12) 6 (10)
Nodal status
N 0 14 (40) 25 (42)
N 1 14 (40) 18 (30)
N 2 6 (17) 17 (28)
N 3 1 (3) —
Distant metastasis
M 0 26 (74) 37 (62)
M 1 9 (26) 23 (38)
TNM staging
Stage I 10 (29) 7 (12)
Stage II 8 (23) 13 (22)
Stage III 6 (17) 16 (27)
Stage IV 11 (31) 23 (38)
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sBevely, MA, USA) and then subjected to bisulphite treatment was
used as a positive control for methylated alleles. Water blanks were
included in each assay.
5-Aza-CdR and TSA treatment
Cell lines were treated with 5-Aza-CdR (Sigma-Aldrich Co., St
Louis, MO, USA) at a concentration of 1–2mgml
 1 for 6 days with
medium changes on days 1, 3 and 5 (Jones, 1985; Virmani et al,
2000). The treatment with histone deacetylase inhibitor, TSA
(Wako, Tokyo, Japan), was performed at a concentration of 150–
300nM for 12–24h (Yoshida et al, 1990; Toyooka et al, 2002a). For
combination treatment, TSA was added to day 5 of 5-Aza-CdR-
treated cell lines and cultured for additional 12–24h. Treated or
untreated cells from individual triplicate flasks were harvested to
be semiquantified by the gene expression level using real-time
RT–PCR as described above.
Statistical analysis
The frequencies of hDAB2IP methylation between two groups were
compared using the w
2 test. The quantitative ratios of different
groups were compared using the Mann–Whitney U-nonpara-
metric test. Probability value less than 0.05 was defined as being
statistically significant. All data were analysed with StatView for
Windows (SAS Institute Inc., Cary, NC, USA).
RESULTS
Bisulphited genomic DNA sequencing
The m2a and m2b regions, covering the major part of the P2
region, were separately amplified by PCR to examine their
methylation status by direct sequencing in eight gastric cancer
cell lines, and five cell lines that showed one of the four typical
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Figure 1 Map of 50 flanking region of hDAB2IP gene and the bisulphited genomic DNA sequence. (A) Location of CpG dinucleotides in the genomic
sequence (GenBank accession number AL365274) are indicated by thin vertical lines. The bent arrow indicates the transcription start site (TSS) (þ1). Five
rectangular boxes, promoter region (P2), regions for the bisulphited genomic sequence (m2a: from  522 to  285, m2b: from  308 to þ89) and regions
for the amplicons of MSP (RMSPm2a, RMSPm2b). (B) Methylation status of individual cloned DNA fragments of five gastric cancer cell lines is shown. Each
row represents one sequenced allele. Each circle represents a CpG dinucleotide. Filled circle, methylation; open circle, no methylation. Clonal numbers are
indicated by prefix C to the left. The numbers at the top indicate the CpG dinucleotide in the amplicon (50 to 30). The percentage of MA, MB and MT
indicates the rate of methylated CpG dinucleotides in m2a, m2b and total regions of each sample, respectively. ER means expression ratio by
semiquantitative real-time RT–PCR. The location of CpG dinucleotides included in MSP primers (m2a-MSP-F, m2a-MSP-R, m2b-MSP-F and m2b-MSP-R)
are indicated by open boxes. M(þ), positive for the hDAB2IP-methylated form by MSP; M(  ), negative for the hDAB2IP-methylated form by MSP; M( 7),
positive for both the hDAB2IP-methylated and -unmethylated forms by MSP.
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smethylation patterns were selected for more detailed analysis. The
PCR amplicons of these five cell lines were cloned, and eight
individual clones were sequenced (Figure 1B). MKN-1 showed
almost no methylation in either the m2a or the m2b region. In
contrast, NCI-SNU-16 showed a heavy methylation pattern, with
methylation of over 80% of all the CpG dinucleotides in both the
m2a and m2b regions. The other three cell lines showed a
moderate methylation pattern, which was subdivided into two
types, the m2a- and the m2b-dominant methylation pattern. Two
cell lines, namely, MKN-7 and NCI-SNU-5, showed an m2b-
dominant methylation pattern, and one cell line, namely, SH-10
TC, showed an m2a-dominant methylation pattern.
hDAB2IP expression in gastric cancer cell lines
We examined the expression status of hDAB2IP by semiquantita-
tive real-time RT–PCR in eight cell lines, consisting of three
showing heavy methylation in both the m2a and m2b regions, one
showing an m2a-dominant methylation pattern, two showing an
m2b-dominant methylation pattern, and two showing no methyla-
tion of the hDAB2IP gene. The semiquantitatively estimated mRNA
expression values in each cell line are shown in Figure 2A. The
values in the two cell lines showing no methylation of the gene
were as follows; the mean hDAB2IP expression ratio in NUGC-4
was very high at 19.2, as expected, but the ratio in MKN-1 was
quite unexpectedly low, with a value of 1.81. This transcriptional
downregulation of hDAB2IP in MKN-1 was attributed to treatment
with a histone deacetylase inhibitor, as described below. As
compared with the value in NUGC-4, the expression ratios in all of
the cell lines showing methylation of the hDAB2IP gene, with the
exception of SH-10-TC, were significantly lower, with the mean
ratios in NCI-SNU-16, MKN-45, KATO-III, NCI-SNU-5 and MKN-
7 being 2.24, 3.23, 2.08, 1.28, and 3.03 respectively; the expression
ratio in SH-10-TC was only 13.8. SH-10-TC showed a moderate
methylation status with the m2a-dominant pattern, but its m2b
region was almost completely unmethylated, as described above.
On the other hand, in MKN-7 and NCI-SNU-5, in which the
expression ratios indicated significant downregulation of hDA-
B2IP, the m2a-methylation rates were equal to that in SH-10-TC,
but the m2b regions were additionally methylated (Figure 1B).
These results indicate that the expression of hDAB2IP tended to be
reduced depending on the methylation status in the m2b region,
which is just adjacent to the transcriptional-start site, and suggest
that the m2b promoter region might be the methylation-mediated
key regulator of the expression of hDAB2IP in gastric cancer. In
the five nonmalignant gastric mucosal specimens examined, the
mean expression ratio of hDAB2IP was 21.679.7, indicative of
normal expression.
MSP assay and aberrant methylation of hDAB2IP in
gastrointestinal tumours
We determined the forward and reverse primers for MSP of each of
the m2a and m2b regions (Figure 1B). The CpG sites in these
regions were almost consistently methylated in the expression-
reduced cell lines (Figure 1B). Three and four cytosines were
included in the forward and reverse primers, respectively, for the
m2a region producing a 163-bp amplicon, and five and three
cytosines were included in the forward and reverse primers,
respectively, for the m2b region producing a 209-bp amplicon
(Figure 1B). Methylation-specific PCR assay using these primers
was performed to examine the methylation status of hDAB2IP in
the gastric cancer cell lines and in primary gastric and colorectal
cancer tumours. Representative examples of the assay are
illustrated in Figure 3A and B and the results are summarised in
Table 2. Aberrant methylation of the m2a and m2b regions was
found in 16 of 35 (46%) and 15 of 35 (43%) primary gastric cancer
specimens, respectively, and in 29 of 60 (48%) and 28 of 60 (47%)
primary colorectal cancer specimens, respectively. In the case of
the gastric cancer cell lines, methylation of the gene was detected
in eight of 12 cell lines (67%) for each of the m2a and m2b regions.
The unmethylated form of hDAB2IP was always found in primary
tumour samples because these had been grossly dissected and thus
showed some contamination with normal cells. In contrast, the
cancer cell lines consisted of a pure population of tumour cells,
and eight of the 12 cell lines (67%) had either methylated or
unmethylated hDAB2IP alleles for both m2a and m2b regions. Four
of the 12 cell lines (33%) showed both methylated and
unmethylated forms for the m2a or the m2b region, and were
regarded as showing partial methylation of the gene, and the
details of the CpG methylation status in these cell lines are shown
in Figure 1B. A total of 36 (38%) primary gastric and colorectal
cancer specimens and seven (58%) cell lines showed aberrant
methylation in both the m2a and m2b regions. On the other hand,
16 (17%) primary gastric and colorectal cancer specimens and two
(17%) cell lines showed methylation of either the m2a or the m2b
region. There were no significant differences in the methylation
rate between the cancer cell lines and primary tumours in either
the m2a or the m2b region. In addition, seven (12%) and 11 (19%)
of 59 gastrointestinal normal mucosal specimens showed methyla-
tion in the m2a and m2b regions, respectively. Aberrant
methylation was not present in either of the two regions in
samples obtained from five peripheral blood lymphocytes.
5-Aza-CdR and TSA treatment for gastric cancer cell lines
To confirm the involvement of DNA methylation in hDAB2IP
silencing, we treated five cell lines with 5-Aza-CdR. hDAB2IP
expression was upregulated following the 5-Aza-CdR treatment in
the m2b-methylated cell lines. In contrast, no such upregulation
following 5-Aza-CdR treatment was observed in the m2b-
nonmethylated cell lines. This finding indicates that methylation
in the m2b region plays an important role in regulating the gene
silencing. Furthermore, we also treated cell lines with TSA, either
singly or in combination with 5-Aza-CdR. Expression of hDAB2IP
in MKN-7 was upregulated 3.1-fold by TSA treatment and by 6.9-
fold by following combined treatment with TSA and 5-Aza-CdR. In
NCI-SNU-5, while hDAB2IP expression was upregulated 3.0-fold
Figure 2 hDAB2IP mRNA expression using semiquantitative real-time RT–PCR. Triplicate sets of flasks before and after drug treatment were harvested
and tested for gene expression using semiquantitative real-time PCR. Data shown are mean values7s.d., n¼3. (A) The relative ratio of mRNA expression
in each cell line. The relative expression ratio was remarkably repressed in m2b-methylated cell lines compared with m2b-unmethylated ones except MKN-
1. Following symbols of two plus and minus means positive and negative for methylation status by MSP, respectively. One plus means positive for both the
methylated and unmethylated forms by MSP. (B) Effect of 5-Aza-CdR, TSA and combination on mRNA expression in m2b-methylated cell lines (MKN-7,
NCI-SNU-5 and NCI-SNU-16). hDAB2IP expression of MKN-7 was upregulated 3.4-fold by 5-Aza-CdR, 3.1-fold by TSA and additively 6.9-fold by
combination. In NCI-SNU-5, hDAB2IP expression was also upregulated 3.0-fold by 5-Aza-CdR and 3.0-fold by TSA, whereas TSA failed to make synergistic
or additive effect for this cell line. In NCI-SNU-16, the expression was also upregulated 3.1-fold by 5-Aza-CdR, but TSA alone failed to make a positive effect,
operating synergically to 6.6-fold on the expression with a combination of 5-Aza-CdR. (C) Effect of 5-Aza-CdR, TSA and combination on mRNA expression
in m2b-unmethylated cell lines (MKN1 and SH-10-TC). In MKN-1, the downregulated expression was restored 3.1-fold by TSA alone. In SH-10-TC, the
expression was decreased after any drug treatment, which may be caused by a cytotoxic effect from drug exposure.
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Aza-CdR failed to elicit a synergistic or additive effect. In NCI-
SNU-16, while treatment with TSA alone failed to have any positive
effect, combined treatment with 5-Aza-CdR elicited a positive
effect on hDAB2IP expression.
On the other hand, in SH-10-TC, an m2b-nonmethylated cell
line, treatment with the aforementioned drugs neither upregulated
nor downregulated the expression of hDAB2IP (0.1–0.4-fold),
because the number of SH-10-TC cells in culture was decreased by
treatment with 5-Aza-CdR, TSA or a combination of 5-Aza-CdR
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sand TSA (data not shown). This effect may be attributable to the
cytotoxic effect of 5-Aza-CdR and TSA. Interestingly, in MKN-1,
which showed no methylation in either the m2a or the m2b region,
the downregulated expression of hDAB2IP could be restored by
TSA treatment alone. This result suggests that the expression of the
gene might be downregulated under the control of histone
deacetylation in this cell line alone. These results suggest that
both DNA methylation and histone deacetylation may act
cooperatively to silence hDAB2IP expression in some gastric
cancer cell lines, and that the methylation status of the m2b region
may act as the major gene silencing mechanism in most cell lines.
hDAB2IP methylation and clinicopathological correlation
We examined the relationship between the methylation status in
the tumour specimens and clinicopathological factors, including
sex, age, tumour size, extent of tumour invasion, lymph node
status, distant metastasis, TNM stage, histology and the tumour
site in cases with gastrointestinal cancers. In cases of gastric
cancer, while both the m2a- and m2b-methylation status were
significantly associated with the tumour site, the m2b-methylation
status showed a stronger correlation than the m2a-methylation
status (m2a, P¼0.0172; m2b, P¼0.0064; Table 3). In cases of
colorectal cancer, m2b methylation tended to be associated with
cancer arising from the left side of the colon. (P¼0.0926; Table 4).
hDAB2IP methylation was often observed in tumours arising from
the lower-third of the stomach and distal aspect of the colorectum.
There were no significant differences between methylation-positive
and methylation-negative groups with respect to the other factors
examined in this study. Although accumulation of methylation
appears to be age-related in a number of cancer-related genes, both
the m2a- and m2b-methylation status were not significantly
associated with the age of patients (gastric cancer: m2a,
P¼0.9369; m2b, P¼0.9788; colorectal cancer: m2a, P¼0.8484;
m2b, P¼0.5709; Table 5).
DISCUSSION
To determine the methylation status of the 50 CpG islands of
hDAB2IP in gastrointestinal tumours, we first performed bisul-
phite genomic DNA sequencing in several gastric cancer cell lines.
Based on the sequence data, methylation-specific primers were
designed to detect sensitively each methylated or unmethylated
allele (Toyooka et al, 2002b, 2003). These primers have also been
shown to be applicable to lung and breast cancer cell lines (Dote
et al, 2004). Using the MSP primers designed thus, we found
frequent methylation of the hDAB2IP gene in primary gastro-
intestinal tumours, as well as in gastrointestinal tumour cell lines.
The higher frequency of methylation in the cell lines as compared
with that in the primary tumours might be explained by the
additional changes that the cells may acquire in culture, or by the
tumour cell lines being derived from more aggressive tumours and
therefore showing more malignant changes (Zochbauer-Muller
et al, 2001).
Figure 3 Representative examples of MSP in gastrointestinal tumours. (A) gastric cancer cell lines, (B) primary tumours. The unmethylated form of
hDAB2IP was always found in primary tumours that had been grossly dissected and thus had at least some contamination with normal cells. Positive controls
include peripheral blood lymphocytes from healthy individuals for the unmethylated form and normal lymphocyte DNA methylated by treatment with Sss I
DNA methyltransferase for the methylated form.
Table 2 Aberrant promoter methylation of hDAB2IP in samples
Samples
No. of
hDAB2IP
m2a
methylated
samples (%)
No. of
hDAB2IP
m2b
methylated
samples (%)
No. of both
m2a and
m2b
methylated
samples (%)
Gastric cancers
Cell lines (n¼12) 8 (67) 8 (67) 7 (58)
Primary tumours (n¼35) 16 (46) 15 (43) 13 (37)
Colorectal cancers
Primary tumours (n¼60) 29 (48) 28 (47) 23 (38)
Nonmalignant specimens (n¼64)
Normal gastric mucosa
(n¼35)
2 (6) 7 (20) 2 (6)
Normal colorectal mucosa
(n¼24)
5 (21) 4 (17) 3 (13)
Peripheral lymphocytes
(n¼5)
0 (0) 0 (0) 0 (0)
Table 3 Clinicopathologic features and hDAB2IP promoter methylation in gastric cancer
Clinicopathologic features Variable
a
Frequency of hDAB2IP
m2a methylation (%) P-value
b
Frequency of hDAB2IP
m2b methylation (%) P-value
b
Sex Male (n¼21) 8 (38) 0.27 9 (43) 40.99
Female (n¼14) 8 (57) 6 (43)
Tumour invasion T1, 2 (n¼20) 9 (45) 0.92 9 (45) 0.77
T3, 4 (n¼15) 7 (47) 6 (40)
Nodal metastasis N0 (n¼14) 7 (50) 0.68 7 (50) 0.49
N1, 2 (n¼21) 9 (43) 8 (38)
Metastasis M0 (n¼26) 12 (46) 0.93 11 (42) 0.91
M1 (n¼9) 4 (44) 4 (44)
TNM stage 1, 2 (n¼18) 8 (44) 0.88 8 (44) 0.85
3, 4 (n¼17) 8 (47) 7 (41)
Histology Intestinal (n¼17) 8 (47) 0.88 6 (35) 0.38
Diffuse (n¼18) 8 (44) 9 (50)
Tumour site U (n¼7) 2 (22) 0.017 1 (14) 0.0064
M( n¼13) 3 (23) 3 (23)
L( n¼15) 11 (73) 11 (73)
aU¼upper site; M¼middle site; L¼lower site.
bStatistical significance was determined using w
2 test.
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sWe previously reported that the m2a region appeared to be the
key regulatory region for hDAB2IP expression in prostate cancer
(Chen et al, 2003) and that methylation of both the m2a and m2b
regions occurred in breast cancer cell lines (Dote et al, 2004).
However, in contrast to the observation in prostate and breast
cancer, this study demonstrated that the downregulation of
hDAB2IP expression correlated more with the methylation status
of not the m2a region, but of the m2b region, which is located just
adjacent to exon Ia in gastric cancer cell lines (Figure 2A).
Considering the close proximity of the m2b region to the
transcriptional-start site of the hDAB2IP gene, it stands to reason
that the m2b region might act as the regulatory promoter in gastric
cancer cells.
We demonstrated in this study that the expression of hDAB2IP
was highly suppressed in five m2b-methylated cell lines as
compared with that in two m2b-nonmethylated cell lines. This
result suggests that DNA methylation of the regulatory promoter
region may be critical for transcriptional regulation of the
hDAB2IP gene and play an important role in hDAB2IP inactiva-
tion. These results are consistent with the finding of restoration of
hDAB2IP expression in methylated cell lines after 5-Aza-CdR
treatment.
Recent data suggest that hypermethylated DNA interacts with
several methyl-CpG-binding proteins, and that the interaction
facilitates the assembly of a repressive complex containing histone
deacetylase and formation of an inactive chromatin that leads to
gene silencing (Nan et al, 1998; Wade et al, 1999). Therefore, we
examined the effect of the histone deacetylase inhibitor, TSA,
as well as that of 5-Aza-CdR on the methylated cell lines,
to distinguish the effect of histone deacetylation on the down-
regulated gene expression of hDAB2IP. In MKN-7, the expression
was upregulated by both 5-Aza-CdR and TSA treatment,
and combined treatment with both agents caused synergistic
upregulation, with the extent of upregulation in this case
being greater than that with either agent alone. In addition, in
some other methylated cells, TSA enhanced hDAB2IP
gene expression. These results indicate that in some cell lines
showing gene methylation, there may be a synergistic and
positive interaction between DNA methylation and histone
deacetylation for transcriptional regulation, although this
does not seem to be a common and major mechanism in gastric
cancer cells. However, the number of examined cells was
too limited to arrive at any definitive conclusion on the effect
of TSA on hDAB2IP expression. Considering this effect of
deacetylation on gene expression, it was reported that the
expression of some methylation-repressed genes can be reactivated
by TSA treatment (Yang et al, 2000) and that demethylation-
induced gene re-expression could be potentiated by TSA (Cameron
et al, 1999). In addition, Suzuki et al (2002) analysed the
expression of over 10000 genes by microarray analysis, and found
that the expression of 74 genes was upregulated following
treatment with 5-Aza-CdR or TSA. They also showed that
transcriptional silencing is mediated by both methylation and
histone deacetylation, although the effect of methylation was
dominant for gene silencing.
hDAB2IP methylation was found to be present at similar
frequencies in both early and advanced carcinomas, suggesting
that the methylation actually occurs at an early stage of
carcinogenesis in gastrointestinal tumours. Furthermore, the result
that hDAB2IP methylation was found in nonmalignant mucosa
suggested that hDAB2IP methylation might play a causative role in
carcinogenesis. Interestingly, we found a highly significant
association between the tumour location in the stomach and
methylation of the m2b region, which has been supposed to be the
key regulatory sequence, as described above. Cancers showing
methylation of the m2b region showed a significant tendency
towards being preferentially located in the lower-third of the
stomach. Similar results were also described for p16, hMLH1 and
TSLC1 methylation in gastric cancer (Schneider et al, 2000; Honda
et al, 2002; Sakata et al, 2002). Therefore, methylation of several
tumour-suppressor and tumour-related genes appears to be an
important pathogenetic mechanism of gastric cancers arising from
the antrum. Because intestinal metaplasia commonly arises in the
antrum and then extends towards the body of the stomach,
Table 4 Clinicopathologic features and hDAB2IP promoter methylation in colorectal cancer
Clinicopathologic features Variable
a
Frequency of hDAB2IP
m2a methylation (%) P-value
b
Frequency of hDAB2IP
m2b methylation (%) P-value
b
Sex Male (n¼37) 18 (49) 0.95 15 (41) 0.23
Female (n¼23) 11 (48) 13 (57)
Tumour invasion T1, 2 (n¼9) 4 (44) 0.80 5 (56) 0.56
T3, 4 (n¼51) 25 (49) 23 (45)
Nodal metastasis N0 (n¼25) 9 (36) 0.11 11 (44) 0.73
N1, 2 (n¼35) 20 (57) 17 (49)
Metastasis M0 (n¼53) 26 (49) 0.76 25 (47) 0.83
M1 (n¼7) 3 (43) 3 (43)
TNM stage 1, 2 (n¼21) 7 (33) 0.088 9 (43) 0.66
3, 4 (n¼39) 22 (56) 19 (49)
Histological grade G1 (n¼13) 7 (54) 0.65 6 (46) 0.97
G2, 3, 4 (n¼47) 22 (47) 22 (47)
Tumour site C, A, T (n¼12) 4 (33) 0.25 3 (25) 0.093
D, S, R (n¼48) 25 (52) 25 (52)
aC¼cecum; A¼ascending colon; T¼transverse colon; D¼descending colon; S¼sigmoid colon; R¼rectum.
bStatistical significance was determined using w
2 test.
Table 5 Association between hDAB2IP promoter methylation status and
age in gastrointestinal cancer
Methylation status Age
a P-value
b
Gastric cancer
m2a-methylation (n¼15) 66 (40–89) 0.9369
m2a-unmethylation (n¼20) 66 (36–85)
m2b-methylation (n¼16) 66 (40–89) 0.9788
m2b-unmethylation (n¼19) 66 (36–85)
Colorectal cancer
m2a-methylation (n¼29) 66 (51–85) 0.8484
m2a-unmethylation (n¼31) 65 (26–86)
m2b-methylation (n¼28) 66 (47–82) 0.5709
m2b-unmethylation (n¼32) 65 (26–86)
aMean age (range) in years.
bStatistical significance was determined using Mann–
Whitney U-test.
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sintestinal metaplasia may predispose to promoter region methyla-
tion in these genes (Sato et al, 2001). In addition, a marked
increase in the frequency of methylated genes from nonmetaplastic
mucosa to intestinal metaplasia has been reported (Kang et al,
2001). In sporadic colorectal cancers, it has recently been shown
that CpG island methylation is associated with a right-sided
location of the tumour (Hawkins et al, 2002). However, we also
found an inverse association between m2b-region methylation and
a right-sided location of the tumour, although this did not reach
statistical significance.
In conclusion, our results demonstrate that aberrant methyla-
tion drives gene downregulation, and supports the contention that
the methylation-mediated transcriptional silencing of the hDAB2IP
gene may be a critical event in tumorigenesis of gastrointestinal
tumours, especially those arising from the antrum of the stomach
in association with intestinal metaplasia.
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